Bifikafusp alfa
Modify Date: 2024-01-31 12:41:36
Bifikafusp alfa structure
|
Common Name | Bifikafusp alfa | ||
|---|---|---|---|---|
| CAS Number | 1957239-90-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Bifikafusp alfaBifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity[1]. |
| Name | Bifikafusp alfa |
|---|
| Description | Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; 雌性 NMRI 裸鼠 MiaPaca-A2 异种移植) 对已建立的胰腺癌具有抗肿瘤活性[1]。 Animal Model: Female NMRI nude mice with MiaPaca-A2 xenografts[1] Dosage: 1.43 and 4.29 MIU/kg Administration: Intraperitoneal injection; daily; for 10 days Result: Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice. |
| References |
| No Any Chemical & Physical Properties |